tiprankstipranks
Advertisement
Advertisement

TCRX Stock Latest News

TScan Therapeutics: Early ALLOHA Phase 1 Efficacy and Safety Reinforce Late-Stage Plans; Buy Rating and $6 Price Target Maintained
RatingsTScan Therapeutics: Early ALLOHA Phase 1 Efficacy and Safety Reinforce Late-Stage Plans; Buy Rating and $6 Price Target Maintained
18d ago
TCRX
TScan Therapeutics: ALLOHA Data, Streamlined Manufacturing Bolster Buy Rating with $7 Price Target Maintained
PremiumRatings
TScan Therapeutics: ALLOHA Data, Streamlined Manufacturing Bolster Buy Rating with $7 Price Target Maintained
18d ago
TCRX
TScan Therapeutics Advances TSC-101 Toward Pivotal Trial
PremiumCompany Announcements
TScan Therapeutics Advances TSC-101 Toward Pivotal Trial
19d ago
8K
TCRX
TScan Therapeutics presents data from Cohort C of ALLOHA trial
PremiumThe Fly
TScan Therapeutics presents data from Cohort C of ALLOHA trial
19d ago
TCRX
TScan Therapeutics, Cellares enter agreement to evaluate TCS-101 manufacturing
PremiumThe Fly
TScan Therapeutics, Cellares enter agreement to evaluate TCS-101 manufacturing
1M ago
TCRX
TScan Therapeutics Expands Authorized Shares After Stockholder Vote
PremiumCompany AnnouncementsTScan Therapeutics Expands Authorized Shares After Stockholder Vote
2M ago
8K
TCRX
Buy Rating Reiterated on TSC-101 Ahead of Key ALLOHA Readouts and Pipeline Expansion; $6 Price Target Maintained
Premium
Ratings
Buy Rating Reiterated on TSC-101 Ahead of Key ALLOHA Readouts and Pipeline Expansion; $6 Price Target Maintained
2M ago
TCRX
TScan Therapeutics reports Q1 EPS (22c), consensus (17c)
Premium
The Fly
TScan Therapeutics reports Q1 EPS (22c), consensus (17c)
2M ago
TCRX
TScan Therapeutics Consolidates Finance Leadership After Officer Resignation
PremiumCompany Announcements
TScan Therapeutics Consolidates Finance Leadership After Officer Resignation
3M ago
8K
TCRX
Buy 2 ‘Strong Buy’ Biotech Stocks With 400%+ Upside, According to Wall Street
PremiumMarket News
Buy 2 ‘Strong Buy’ Biotech Stocks With 400%+ Upside, According to Wall Street
4M ago
CRVO
TCRX
TScan Therapeutics price target raised to $5 from $4 at Wedbush
PremiumThe Fly
TScan Therapeutics price target raised to $5 from $4 at Wedbush
4M ago
TCRX
TScan Therapeutics: Strengthening Heme-Focused TCR-T Platform and Regulatory Momentum Support Buy Rating and $7 Target
PremiumRatings
TScan Therapeutics: Strengthening Heme-Focused TCR-T Platform and Regulatory Momentum Support Buy Rating and $7 Target
4M ago
TCRX
TScan Therapeutics reports Q4 EPS (18c), consensus (28c)
PremiumThe FlyTScan Therapeutics reports Q4 EPS (18c), consensus (28c)
4M ago
TCRX
TScan Therapeutics sees cash runway into 2H27
Premium
The Fly
TScan Therapeutics sees cash runway into 2H27
4M ago
TCRX
TScan Therapeutics: Clinical Momentum in TSC-101 and Pipeline Expansion Underpin Buy Rating Despite Cash Constraints
Premium
Ratings
TScan Therapeutics: Clinical Momentum in TSC-101 and Pipeline Expansion Underpin Buy Rating Despite Cash Constraints
4M ago
TCRX
TScan Therapeutics completes enrollment into Cohort C of ALLOHA study
PremiumThe Fly
TScan Therapeutics completes enrollment into Cohort C of ALLOHA study
5M ago
TCRX
TScan Therapeutics Outlines Pivotal 2026 Outlook in Presentation
PremiumCompany Announcements
TScan Therapeutics Outlines Pivotal 2026 Outlook in Presentation
6M ago
8K
TCRX
Hold Rating for TScan Therapeutics Amid Promising Data and Awaited Future Developments
PremiumRatings
Hold Rating for TScan Therapeutics Amid Promising Data and Awaited Future Developments
7M ago
TCRX
TScan Therapeutics: Overcoming Manufacturing Setbacks with Strategic Adjustments and Promising Potential in Myeloid Malignancies
PremiumRatings
TScan Therapeutics: Overcoming Manufacturing Setbacks with Strategic Adjustments and Promising Potential in Myeloid Malignancies
7M ago
TCRX
Promising Potential of TScan Therapeutics’ TSC-101: Analyst Recommends Buy Rating
PremiumRatingsPromising Potential of TScan Therapeutics’ TSC-101: Analyst Recommends Buy Rating
7M ago
TCRX
TScan Therapeutics announces updated data from ALLOHA Phase 1 trial
Premium
The Fly
TScan Therapeutics announces updated data from ALLOHA Phase 1 trial
7M ago
TCRX
TScan Therapeutics Approves Key Employee Retention Program
Premium
Company Announcements
TScan Therapeutics Approves Key Employee Retention Program
8M ago
8K
TCRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >